ALX Oncology is a clinical-stage immuno-oncology company developing therapies that block the CD47 myeloid checkpoint mechanism exploited by cancer cells to evade the immune system. Our lead candidate, ALX148, is a first-in-class fusion protein that comprises an engineered high affinity CD47 binding domain of SIRPα linked to an inactive Fc region of human immunoglobulin. ALX148 is designed to enhance the efficacy of antibody-based therapies and is in clinical development for a broad range of tumor types.
October 2, 2019 – ALX Oncology to Present ALX148 Clinical Biomarker Data at the 34th Annual Meeting of the Society for Immunotherapy of Cancer (SITC)
August 12, 2019 – Eat This, Don’t Eat That: CD47 Companies’ First Hurdle
June 1, 2019 – ALX Oncology Presents New Data from Fully Enrolled ALX148 Clinical Trial Combination Cohorts for the Treatment of Patients with Advanced Solid Tumors